PDL BioPharma Net Cash Flow 2010-2020 | PDLI

PDL BioPharma net cash flow from 2010 to 2020. Net cash flow can be defined as the total change in cash for the company over the given period.

PDL BioPharma Net Cash Flow 2010-2020 | PDLI

PDL BioPharma net cash flow from 2010 to 2020. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$222.7B
Amgen (AMGN)$161.5B
Gilead Sciences (GILD)$142.5B
Vertex Pharmaceuticals (VRTX)$123.1B
Bristol Myers Squibb (BMY)$98.7B
GSK (GSK)$81B
CSL (CSLLY)$78.2B
Regeneron Pharmaceuticals (REGN)$60.4B
Alnylam Pharmaceuticals (ALNY)$42.1B
Argenex SE (ARGX)$34.4B
BioNTech SE (BNTX)$27.4B
Royalty Pharma (RPRX)$20.3B
Biogen (BIIB)$19.8B
Insmed (INSM)$18.3B
Illumina (ILMN)$15.8B
Genmab (GNMSF)$14B
Genmab (GMAB)$14B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.3B
Exelixis (EXEL)$12.3B
BioMarin Pharmaceutical (BMRN)$11.3B
QIAGEN (QGEN)$10.8B
Ascendis Pharma (ASND)$10.8B
Swedish Orphan Biovitrum (BIOVF)$10.4B
Exact Sciences (EXAS)$10.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.5B
Blueprint Medicines (BPMC)$8.4B
Regencell Bioscience Holdings (RGC)$8.2B
Roivant Sciences (ROIV)$7.9B